The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Ofri Mosenzon, MD, MSc
Ofri Mosenzon is a professor of Internal medicine and Endocrinology in the faculty of Medicine, Hebrew university of Jerusalem, Israel. She is also the manager of the Diabetes Clinical Research Center at the Hadassah Medical Center, Jerusalem, Israel. Prof. Mosenzon received her medical degree from the Faculty of Medicine, Technion, Haifa, Israel. She is board-certified in Internal Medicine and Endocrinology and has an MSc in Clinical Epidemiology from the Hebrew University of Jerusalem. Prof. Mosenzon’s research interests include, but are not limited to, cardiovascular and renal outcomes trials with glucagon-like peptide-1 receptor analogues, and sodium-glucose co-transporter 2 inhibitors. She has led many peer-reviewed publications, and lecture extensively worldwide.